What did this study find?
This 2023 randomized trial enrolled 182 patients with neuropathic pain. A thirty percent reduction against sham was observed in the subgroup whose devices were correctly placed, not in the trial population as a whole. Subgroup findings are weaker evidence than a whole-population result and require confirmation before they guide practice.
What are the details of this record?
- Full citation
- PEMF for Neuropathic Pain: RCT. 2023. PMID: 37542366.
- Study design
- Randomized controlled trial
- Sample size and population
- 182 patients
- Evidence grade
- Grade C+ on the BioReg grading scale
- Reported findings
- 30% pain reduction vs sham in active-treatment subgroup without device-placement problem.
- DOI
- No DOI recorded
- PubMed
- PMID 37542366
- Related categories
- Neuropathic Pain (category grade C+)
A positive PEMF study is not evidence for a specific device unless the signal parameters studied, frequency, intensity, waveform, and exposure duration, are reasonably comparable to what that device produces. Where this record does not list those parameters, the source report did not publish them. See the grading methodology. Library last reviewed 2026-08-27.